                                                                                                                   
                                                   UNITED STATES                                                   
                                                                                                                   
                                                                                                                   
                                        SECURITIES AND EXCHANGE COMMISSION                                         
                                                                                                                   
                                                                                                                   
                                               WASHINGTON, DC 20549                                                
                                                                                                                   
                                                                                                                   
                                                     FORM 8-K                                                      
                                                                                                                   
                                                  CURRENT REPORT                                                   
                                                                                                                   
                                      Pursuant to Section 13 or 15(d) of The                                       
                                                                                                                   
                                          Securities Exchange Act of 1934                                          
                                                                                                                   
                                 Date of report (Date of earliest event reported):                                 
                                                                                                                   
                                                 December 3, 2020                                                  
                                                                                                                   
                                                 Johnson & Johnson                                                 
                                                                                                                   
                              (Exact name of registrant as specified in its charter)                               
                                                                                                  
  New Jersey                         1-3215                     22-1024240                        
  (State or Other Jurisdiction of    -Commission File Number    -IRS Employer Identification No.  
  Incorporation)                                                                                  
                                                                                                  
                           One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933                            
                                                                                                                   
                                     (Address of Principal Executive Offices)                                      
                                                                                                                   
                                                    (Zip Code)                                                     
                                                                                                                   
                                Registrant's telephone number, including area code:                                
                                                                                                                   
                                                   732- 524-0400                                                   
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:
                                                                                                    
  Title of each class               Trading Symbol(s)    Name of each exchange on which registered  
  Common Stock, Par Value $1.00     JNJ                  New York Stock Exchange                    
  0.250% Notes Due January 2022     JNJ22                New York Stock Exchange                    
  0.650% Notes Due May 2024         JNJ24                New York Stock Exchange                    
  5.50% Notes Due November 2024     JNJ24BP              New York Stock Exchange                    
  1.150% Notes Due November 2028    JNJ28                New York Stock Exchange                    
  1.650% Notes Due May 2035         JNJ35                New York Stock Exchange                    
                                                                                                    
Item 5.02(d). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.

Johnson & Johnson (the "Company") announced on December 3, 2020, that Dr. Nadja West, retired United States Army
lieutenant general and former United States Army Surgeon General, has been appointed to its Board of Directors (the
"Board"), effective immediately. Dr. West will serve as a member of the Board’s Science, Technology &
Sustainability Committee, effective as of January 1, 2021. As a non-employee Director of the Company, Dr. West will
receive compensation as described in the “Director Compensation” section of the Company's 2020 Proxy Statement.

The Company's press release announcing the appointment is attached to this Report as Exhibit 99.1.
                                                                                                                   
  Item 9.01. Exhibits                                                                                              
                                                                                                                   
(d) Exhibits.
                                                                                                                   
  Exhibit No. Description of Exhibit                                                                               
                                                                                                                   
99.1 Johnson & Johnson Press Release dated December 3, 2020.
                                                                                                                   
                                                    SIGNATURES                                                     
                                                                                                                   
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
                                                                      
                               Johnson &         (Registrant)         
  Date:    December 3, 2020    Johnson    By:    /s/ Matthew Orlando  
 ──────────────────────────────────────────────────────────────────── 
                                                 Matthew Orlando      
                                                 Corporate Secretary  
                                                                      
